- Home
- BCLI vs AAME Comparison
BCLI vs AAME Comparison
Compare BCLI & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- AAME
- Stock Information
- Founded
- BCLI 2000
- AAME 1968
- Country
- BCLI United States
- AAME United States
- Employees
- BCLI N/A
- AAME N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- AAME Life Insurance
- Sector
- BCLI Health Care
- AAME Finance
- Exchange
- BCLI Nasdaq
- AAME Nasdaq
- Market Cap
- BCLI 9.8M
- AAME 35.9M
- IPO Year
- BCLI N/A
- AAME N/A
- Fundamental
- Price
- BCLI $1.16
- AAME $2.34
- Analyst Decision
- BCLI Strong Buy
- AAME
- Analyst Count
- BCLI 1
- AAME 0
- Target Price
- BCLI $30.00
- AAME N/A
- AVG Volume (30 Days)
- BCLI 409.2K
- AAME 22.4K
- Earning Date
- BCLI 08-13-2025
- AAME 08-13-2025
- Dividend Yield
- BCLI N/A
- AAME 0.85%
- EPS Growth
- BCLI N/A
- AAME N/A
- EPS
- BCLI N/A
- AAME N/A
- Revenue
- BCLI N/A
- AAME $191,355,000.00
- Revenue This Year
- BCLI N/A
- AAME N/A
- Revenue Next Year
- BCLI N/A
- AAME N/A
- P/E Ratio
- BCLI N/A
- AAME N/A
- Revenue Growth
- BCLI N/A
- AAME 2.04
- 52 Week Low
- BCLI $0.72
- AAME $1.25
- 52 Week High
- BCLI $6.45
- AAME $2.61
- Technical
- Relative Strength Index (RSI)
- BCLI 49.98
- AAME 83.26
- Support Level
- BCLI $1.02
- AAME $1.94
- Resistance Level
- BCLI $1.32
- AAME $2.61
- Average True Range (ATR)
- BCLI 0.09
- AAME 0.16
- MACD
- BCLI -0.00
- AAME 0.05
- Stochastic Oscillator
- BCLI 46.67
- AAME 81.40
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.